Transformational automation accelerates time to results by up to 93.6% for cytogenetics laboratories worldwide

Leica Biosystems, a Danaher company and a global leader in digital and anatomic pathology solutions, launches its breakthrough AI-Powered  Karyotyping functionality on the CytoInsight GSL platform, marking a major technological advancement for cytogenetics laboratories seeking faster  turnaround times, greater automation, and elevated consistency in chromosome analysis.

This next-generation capability introduces AI-driven karyotype creation that reduces hands-on time by up to 93.6%, dramatically accelerating the  time from metaphase capture to final report. With greater than 99% accuracy in chromosome segmentation and classification, the new AI engine  delivers consistent quality, increases lab efficiency, and enables cytogeneticists to focus their time on higher-value tasks.

“Launching AI-Powered Karyotyping on CytoInsight GSL reinforces our commitment to delivering innovation that drives real impact for  laboratories,” said Naveen Chandra, Vice President & General Manager of Digital Pathology at Leica Biosystems. “By integrating advanced AI into  cytogenetic workflows, we are redefining what’s possible; accelerating turnaround times, enabling scale, and delivering the consistency labs need in a  field where speed and accuracy are critical.”

Designed for flexibility and broad applicability, the AI-Powered Karyotyping module supports a wide array of sample types commonly processed in cytogenetics labs, including:

• Amniotic fluid
• Peripheral blood
• Bone marrow

The new AI-powered Karyotyping capability is fully integrated within the robust CytoInsight GSL ecosystem, complementing the platform’s  comprehensive suite of scanning, capture, analysis, and reporting tools across both Brightfield and FISH workflows.

For Research Use Only. Not For Use In Diagnostic Procedures.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only  company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step.  The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a  Danaher Corporation subsidiary.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human  health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.  Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time  and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous  improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while  setting the foundation for a healthier, more sustainable tomorrow.